Parse

Parse indexes AI recommendations so brands know where they stand.

Products

  • Brands
  • Markets
  • Integrations
  • Work with us
  • Pricing
  • MCP

Resources

  • Research
  • Methodology
  • Blog

© 2026 Parse. All rights reserved.

LegalPrivacy PolicyTerms of Service
Parse
Work with usPricing
Sign inCheck your brand
  1. Brands
  2. Ultragenyx
BrandsUltragenyx

How AI describes Ultragenyx

Data as of Aug 25, 2026 · Based on 3,181,687 AI responses across 10,525 prompts · See how Parse measures this

Ultragenyx logoUltragenyxultragenyx.com

Ultragenyx is a biopharmaceutical company focused on developing and commercializing innovative medicines for rare and ultra-rare diseases. The company has a robust clinical pipeline and aims to deliver transformative therapies for conditions that have never been treated before.

Parse Score

41.4

#67 of 127 in Biopharma Research Platforms and Services

Strength2/ 100
Reach22/ 100
Authority28/ 100

Work at Ultragenyx?

Claim this profile for the full report: every prompt where Ultragenyx appears, who is gaining, and what AI says about you. Claiming is free. Ongoing monitoring is a paid upgrade.

Verified with a work email.

Sources

clinicaltrialsarena.com shapes more of what AI says about Ultragenyx than any other source, at 50% of its citations.

pmc.ncbi.nlm.nih.gov

AI questions where Ultragenyx appears

Always know where you stand in AI

Monitor Ultragenyx

The market map

Biopharma Research Platforms and Services →
10%20%Category leadersSpecialistsIn the mixLong tailNamed in more AI answers →Appears earlier in the answer →OlinkU.S. Food and Dr…Insilico MedicineRecursionNVIDIAUniversity of Co…Alamar BiosciencesBioptimusIBMPharma.aiAlphabetQuanterixIsomorphic LabsNational Institu…

Where AI ranks Ultragenyx

Biopharma Research Platforms and Services#67

  • Excerpts where Ultragenyx appeared in the AI's answer

    Google AI Mode · excerpt
    Ultragenyx Pharmaceutical: Advancing complex gene therapies for ultra-rare metabolic disorders—such as UX111 for Sanfilippo syndrome—using progressive commercialization and pricing models.